FDA Greenlights Imfinzi for Treatment of Limited-Stage Small Cell Lung Cancer in the United States
The United States Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) for adult patients diagnosed with limited-stage small cell lung cancer (LS-SCLC) whose disease remains stable following a regimen of concurrent platinum-based chemotherapy and radiotherapy. The FDA’s decision […]